NFC-1

DRUG3 trials

Sponsors

Aevi Genomic Medicine, LLC, a Cerecor company

Conditions

22q11.2 Deletion SyndromeAttention Deficit Disorder With HyperactivityAttention-deficit Hyperactivity Disorder (ADHD)

Phase 1

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

CompletedNCT02286817

Aevi Genomic Medicine, LLC, a Cerecor companyAttention-deficit Hyperactivity Disorder (ADHD)

Start: 2015-01-31End: 2016-03-31Updated: 2025-10-21

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

CompletedNCT02895906

Aevi Genomic Medicine, LLC, a Cerecor company22q11.2 Deletion Syndrome

Start: 2016-11-28End: 2017-04-20Updated: 2022-03-25

Phase 2

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

CompletedNCT02777931

Aevi Genomic Medicine, LLC, a Cerecor companyAttention Deficit Disorder With Hyperactivity

Start: 2016-06-30End: 2017-02-17Updated: 2021-08-11

Related Papers

Rare recurrent copy number variations in metabotropic glutamate receptor interacting genes in children with neurodevelopmental disorders.

2023-04-299 citations

An electronic health record (EHR) phenotype algorithm to identify patients with attention deficit hyperactivity disorders (ADHD) and psychiatric comorbidities.

2022-06-1118 citations

Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.

2018-01-1646 citations